Jinesh S. Gheeya

Oncology

300 W 10th Ave
Columbus, OH 43210

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 25 publications

Methylation-based liquid biopsy facilitates early detection of small cell transformation in ALK-rearranged non-small cell lung cancer.

Methylation-based liquid biopsy facilitates early detection of small cell transformation in ALK-rearranged non-small cell lung cancer.

Journal: The oncologist

Published: May 03, 2026

CLO26-084: Prognostic Value of Sarcopenia in Patients With Metastatic NSCLC Receiving First-Line Immune Checkpoint Inhibitors.

CLO26-084: Prognostic Value of Sarcopenia in Patients With Metastatic NSCLC Receiving First-Line Immune Checkpoint Inhibitors.

Journal: Journal of the National Comprehensive Cancer Network : JNCCN

Published: April 30, 2026

CLO26-114: Association Between Neoadjuvant Chemoimmunotherapy-Induced Anemia and Survival in Patients With Resectable Non-Small Cell Lung Cancer.

CLO26-114: Association Between Neoadjuvant Chemoimmunotherapy-Induced Anemia and Survival in Patients With Resectable Non-Small Cell Lung Cancer.

Journal: Journal of the National Comprehensive Cancer Network : JNCCN

Published: April 30, 2026

CLO26-084: Prognostic Value of Sarcopenia in Patients With Metastatic NSCLC Receiving First-Line Immune Checkpoint Inhibitors.

CLO26-084: Prognostic Value of Sarcopenia in Patients With Metastatic NSCLC Receiving First-Line Immune Checkpoint Inhibitors.

Journal: Journal of the National Comprehensive Cancer Network : JNCCN

Published: March 30, 2026

CLO26-114: Association Between Neoadjuvant Chemoimmunotherapy-Induced Anemia and Survival in Patients With Resectable Non-Small Cell Lung Cancer.

CLO26-114: Association Between Neoadjuvant Chemoimmunotherapy-Induced Anemia and Survival in Patients With Resectable Non-Small Cell Lung Cancer.

Journal: Journal of the National Comprehensive Cancer Network : JNCCN

Published: March 30, 2026

Expanding the Understanding of Polymerase Epsilon in Pancreatic Cancer: Immune Checkpoint Inhibitor Response in Polymerase Epsilon P286R-Mutated Metastatic Pancreatic Adenocarcinoma.

Expanding the Understanding of Polymerase Epsilon in Pancreatic Cancer: Immune Checkpoint Inhibitor Response in Polymerase Epsilon P286R-Mutated Metastatic Pancreatic Adenocarcinoma.

Journal: JCO precision oncology

Published: December 10, 2025

Impact of immune-related and non-immune related hospital admissions on survival of patients with non-small cell lung cancer receiving first-line immunotherapy.

Impact of immune-related and non-immune related hospital admissions on survival of patients with non-small cell lung cancer receiving first-line immunotherapy.

Journal: Lung cancer (Amsterdam, Netherlands)

Published: August 07, 2025

Tarlatamab-Induced Tumor Lysis Syndrome in Small Cell Carcinoma: Case Series.

Tarlatamab-Induced Tumor Lysis Syndrome in Small Cell Carcinoma: Case Series.

Journal: Clinical lung cancer

Published: July 18, 2025

CLO25-053: Real-World Evidence of Survival in Patients With Metastatic NSCLC Treated With First-Line Immune Checkpoint Inhibitors Beyond Progression.

CLO25-053: Real-World Evidence of Survival in Patients With Metastatic NSCLC Treated With First-Line Immune Checkpoint Inhibitors Beyond Progression.

Journal: Journal of the National Comprehensive Cancer Network : JNCCN

Published: March 30, 2025

CLO25-080: Outcomes of Extreme Low PD-L1 Expression in Advanced Non-Small Cell Lung Cancer: Implications for Treatment Approaches.

CLO25-080: Outcomes of Extreme Low PD-L1 Expression in Advanced Non-Small Cell Lung Cancer: Implications for Treatment Approaches.

Journal: Journal of the National Comprehensive Cancer Network : JNCCN

Published: March 28, 2025

Trends in Pleural Mesothelioma Incidence and Survival in Metropolitan and Nonmetropolitan Areas in the United States.

Trends in Pleural Mesothelioma Incidence and Survival in Metropolitan and Nonmetropolitan Areas in the United States.

Journal: Cancer medicine

Published: March 06, 2025

Tyrosine Kinase Inhibitors Outperform Immune Checkpoint Inhibitors in Bone-Predominant Metastatic Renal Cell Carcinoma: A Multicenter Real-World Analysis.

Tyrosine Kinase Inhibitors Outperform Immune Checkpoint Inhibitors in Bone-Predominant Metastatic Renal Cell Carcinoma: A Multicenter Real-World Analysis.

Journal: Journal of Cancer

Published: March 05, 2025

Showing 1-12 of 25

Last Updated: 09/26/2026